Mark Ragosa Sells 17,845 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the sale, the chief financial officer directly owned 12,086 shares in the company, valued at $523,082.08. This trade represents a 59.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Mark Ragosa also recently made the following trade(s):

• On Thursday, January 8th, Mark Ragosa sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.89, for a total value of $502,680.00.
• On Monday, December 8th, Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ:KNSA traded up $0.27 during trading hours on Wednesday, hitting $44.98. 338,647 shares of the company were exchanged, compared to its average volume of 634,671. Kiniksa Pharmaceuticals International, plc has a 52-week low of $18.25 and a 52-week high of $45.50. The company’s 50 day moving average price is $41.97 and its 200-day moving average price is $38.63. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of 99.96 and a beta of 0.06.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Financiere des Professionnels Fonds d investissement inc. bought a new stake in Kiniksa Pharmaceuticals International during the fourth quarter worth $222,000. Deutsche Bank AG raised its stake in Kiniksa Pharmaceuticals International by 18.2% in the fourth quarter. Deutsche Bank AG now owns 630,291 shares of the company’s stock valued at $26,000,000 after purchasing an additional 96,916 shares in the last quarter. Fox Run Management L.L.C. lifted its stake in Kiniksa Pharmaceuticals International by 105.0% during the fourth quarter. Fox Run Management L.L.C. now owns 27,804 shares of the company’s stock worth $1,147,000 after purchasing an additional 14,241 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $204,000. Finally, Los Angeles Capital Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 29.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 23,659 shares of the company’s stock valued at $976,000 after purchasing an additional 5,376 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on KNSA shares. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.33.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.